Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
48.11
+0.49 (+1.03%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
May 10, 2024
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
May 10, 2024
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy.
Via
Benzinga
2 Beaten-Down Stocks to Buy and Hold for 10 Years
May 10, 2024
They offer plenty of upside and solid dividend growth.
Via
The Motley Fool
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
May 10, 2024
Via
Benzinga
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
April 30, 2024
Via
Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
April 29, 2024
Via
Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 07, 2024
Via
Benzinga
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
May 07, 2024
Via
Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
May 07, 2024
From
Bristol Myers Squibb
Via
Business Wire
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
May 06, 2024
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time.
Via
InvestorPlace
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
May 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Uncover the Potential: 3 Discounted Stocks Ready for a Comeback
May 06, 2024
Investors should considered these discounted stocks to buy for generous returns due to current undervaluation and strong fundamentals.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
May 03, 2024
Via
Benzinga
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
May 03, 2024
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock.
Via
The Motley Fool
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
May 03, 2024
The answer isn't great, but there's still reason to like Bristol Myers Squibb.
Via
The Motley Fool
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 01, 2024
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases
From
Editas Medicine, Inc.
Via
GlobeNewswire
3 Top ETFs to Buy for Passive Income in May
May 01, 2024
These ETFs provide investors with above-average income streams.
Via
The Motley Fool
Topics
ETFs
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
April 28, 2024
10 worst performing large-cap stocks last week: LKQ, MSCI, TXT, EDU, BMY, MANH, RS, META, LUV, NUE. Analysts cut price targets for many.
Via
Benzinga
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
April 26, 2024
Via
Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
April 26, 2024
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
Via
Investor's Business Daily
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
April 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
April 26, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
April 25, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 25, 2024
Via
Benzinga
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
April 25, 2024
Discover Bristol Myers Squibb's impressive first-quarter performance, with revenues exceeding expectations driven by key products like Eliquis and Reblozyl. Despite challenges, the company aims for...
Via
Benzinga
PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal
April 25, 2024
Palantir stock is slipping on Thursday even as PLTR traders learn of a new contract between the data company and Parexel.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.